Health
Symptoms from excessive screen time cost the U.S. $73 billion a year, study finds
American workers are spending too much time looking at screens. More than 104 million people in the U.S., including nearly 70% of people working office jobs, spend upwards of seven hours a day looking at screens, according to a Tuesday report from the Deloitte Economics Institute and the American Optometric Association. As a result, symptoms […]
Read More
Pfizer beats earnings estimates as declining Covid business performs better than expected
Pfizer CEO Albert Bourla talks during a press conference with European Commission President Ursula von der Leyen after a visit to oversee the production of the Pfizer-BioNtech COVID-19 vaccine at the factory of U.S. pharmaceutical company Pfizer in Puurs, Belgium April 23, 2021. John Thys | Reuters Pfizer on Tuesday posted a surprise adjusted fourth-quarter […]
Read More
Big pharma is at a crossroads, as J&J, Merck and others prepare to lose heaps of revenue from blockbuster drugs
The New York Stock Exchange welcomes Johnson & Johnson (NYSE: JNJ) to the podium. NYSE Big pharmaceutical companies such as Bristol Myers Squibb, Merck and Johnson & Johnson face a looming threat that will put tens of billions of dollars in sales at risk between now and 2030, as blockbuster drugs will tumble off a […]
Read More
Merck, Johnson & Johnson CEOs agree to testify in Senate hearing on high drug prices
US Senator Bernie Sanders, Independent of Vermont, speaks during a rally by the People’s Action, protesting pharmaceutical companies’ lobbying against allowing Medicare to negotiate lower prescription drug prices, outside Pharmaceutical Research and Manufacturers of America (PhRMA) headquarters in Washington, DC, September 21, 2021. Saul Loeb | AFP | Getty Images The CEOs of Merck and […]
Read More
Analysts love these biotech stocks, giving 4 more than 100% upside
The health-care sector may have done poorly in the last couple of years, but analysts are bullish on it right now . “Just two weeks into 2024, the healthcare sector has shrugged off the title of being a notable laggard in 2023,” Citi said in a recent note. Higher interest rates were a key headwind, […]
Read More
Eli Lilly's Zepbound is off to a strong start, but here's what needs to happen to push shares higher
Hopes are sky-high for Eli Lilly’s recently launched weight loss drug Zepbound. Investors will be tuning into the company’s fourth quarter earnings call on Feb. 6, eager to hear more about how that rollout is going. One key statistic will be the number of commercial health insurers providing coverage of the drug, which was approved […]
Read More
Tyson Foods drops CVS for upstart pharmacy benefit manager, as industry upheaval over cost concerns spreads
Tyson Foods Inc., sign at Tyson headquarters in Springdale, Ark. April L. Brown | AP Tyson Foods will become one of the first Fortune 100 companies to stop using the nation’s traditional large pharmacy benefits managers, as it looks to cut spending on high-cost drugs. After putting its benefits contract up for bid, Tyson […]
Read More
Johnson & Johnson to settle talc baby powder investigation, will reportedly pay $700 million
In this photo illustration, a container of Johnson and Johnson baby powder is displayed on April 05, 2023 in San Anselmo, California. Justin Sullivan | Getty Images Johnson & Johnson has reached a tentative settlement to resolve an investigation by more than 40 states into claims that the company misled patients about the safety of […]
Read More
Johnson & Johnson narrowly tops quarterly estimates as pharmaceutical, medtech sales jump
The stock trading graph of Johnson & Johnson is seen on a smartphone screen. Rafael Henrique | SOPA Images | LightRocket | Getty Images Johnson & Johnson on Tuesday reported fourth-quarter earnings and revenue that narrowly edged out Wall Street’s expectations as sales in the company’s pharmaceutical and medical devices businesses surged. J&J also provided full-year […]
Read More
Gilead stock falls after disappointing lung cancer study results
Sopa Images | Lightrocket | Getty Images Shares of Gilead fell more than 9% on Monday after a key drug from the company did not significantly extend the lives of patients with a certain lung cancer in a late-stage trial. The results are a blow to Gilead, which is working to become a power player […]
Read More